Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study
Purpose COViK, a prospective hospital-based multicenter case-control study in Germany, aims to assess the effectiveness of COVID-19 vaccines against severe disease. Here, we report vaccine effectiveness (VE) against COVID-19-caused hospitalization and intensive care treatment during the Omicron wave. Methods We analyzed data from 276 cases with COVID-19 and 494 control patients recruited in 13 hospitals from 1 December 2021 to 5 September 2022. We calculated crude and confounder-adjusted VE estimates. Results 21% of cases (57/276) were not vaccinated, compared to 5% of controls (26/494; p < 0.001). Confounder-adjusted VE against COVID-19-caused hospitalization was 55.4% (95% CI: 12–78%), 81.5% (95% CI: 68–90%) and 95.6% (95%CI: 88–99%) after two, three and four vaccine doses, respectively. VE against hospitalization due to COVID-19 remained stable up to one year after three vaccine doses. Conclusion Three vaccine doses remained highly effective in preventing severe disease and this protection was sustained; a fourth dose further increased protection..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Infection - 51(2023), 4 vom: 13. März, Seite 1093-1102 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Stoliaroff-Pepin, Anna [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1007/s15010-023-02012-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC214451836X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC214451836X | ||
| 003 | DE-627 | ||
| 005 | 20240118095504.0 | ||
| 007 | tu | ||
| 008 | 240118s2023 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s15010-023-02012-z |2 doi | |
| 035 | |a (DE-627)OLC214451836X | ||
| 035 | |a (DE-He213)s15010-023-02012-z-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 070 |a 610 |q VZ |
| 100 | 1 | |a Stoliaroff-Pepin, Anna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Purpose COViK, a prospective hospital-based multicenter case-control study in Germany, aims to assess the effectiveness of COVID-19 vaccines against severe disease. Here, we report vaccine effectiveness (VE) against COVID-19-caused hospitalization and intensive care treatment during the Omicron wave. Methods We analyzed data from 276 cases with COVID-19 and 494 control patients recruited in 13 hospitals from 1 December 2021 to 5 September 2022. We calculated crude and confounder-adjusted VE estimates. Results 21% of cases (57/276) were not vaccinated, compared to 5% of controls (26/494; p < 0.001). Confounder-adjusted VE against COVID-19-caused hospitalization was 55.4% (95% CI: 12–78%), 81.5% (95% CI: 68–90%) and 95.6% (95%CI: 88–99%) after two, three and four vaccine doses, respectively. VE against hospitalization due to COVID-19 remained stable up to one year after three vaccine doses. Conclusion Three vaccine doses remained highly effective in preventing severe disease and this protection was sustained; a fourth dose further increased protection. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Vaccine effectiveness | |
| 650 | 4 | |a Hospitalization | |
| 650 | 4 | |a Case-control study | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Omicron | |
| 700 | 1 | |a Peine, Caroline |0 (orcid)0000-0001-6267-3452 |4 aut | |
| 700 | 1 | |a Herath, Tim |4 aut | |
| 700 | 1 | |a Lachmann, Johannes |4 aut | |
| 700 | 1 | |a Hellenbrand, Wiebke |0 (orcid)0000-0002-8563-3629 |4 aut | |
| 700 | 1 | |a Perriat, Delphine |4 aut | |
| 700 | 1 | |a Dörre, Achim |0 (orcid)0000-0001-9297-3675 |4 aut | |
| 700 | 1 | |a Nitsche, Andreas |0 (orcid)0000-0001-8185-3176 |4 aut | |
| 700 | 1 | |a Michel, Janine |0 (orcid)0000-0001-6227-3125 |4 aut | |
| 700 | 1 | |a Grossegesse, Marica |4 aut | |
| 700 | 1 | |a Hofmann, Natalie |4 aut | |
| 700 | 1 | |a Rinner, Thomas |4 aut | |
| 700 | 1 | |a Kohl, Claudia |0 (orcid)0000-0002-1480-8911 |4 aut | |
| 700 | 1 | |a Brinkmann, Annika |0 (orcid)0000-0002-9556-4698 |4 aut | |
| 700 | 1 | |a Meyer, Tanja |0 (orcid)0000-0002-4631-0528 |4 aut | |
| 700 | 1 | |a Stern, Daniel |4 aut | |
| 700 | 1 | |a Treindl, Fridolin |4 aut | |
| 700 | 1 | |a Dorner, Brigitte G. |0 (orcid)0000-0002-5100-2546 |4 aut | |
| 700 | 1 | |a Hein, Sascha |0 (orcid)0000-0001-7257-4538 |4 aut | |
| 700 | 1 | |a Werel, Laura |0 (orcid)0000-0003-2856-8960 |4 aut | |
| 700 | 1 | |a Hildt, Eberhard |4 aut | |
| 700 | 1 | |a Gläser, Sven |4 aut | |
| 700 | 1 | |a Schühlen, Helmut |0 (orcid)0000-0001-8630-4264 |4 aut | |
| 700 | 1 | |a Isner, Caroline |4 aut | |
| 700 | 1 | |a Peric, Alexander |4 aut | |
| 700 | 1 | |a Ghouzi, Ammar |4 aut | |
| 700 | 1 | |a Reichardt, Annette |4 aut | |
| 700 | 1 | |a Janneck, Matthias |4 aut | |
| 700 | 1 | |a Lock, Guntram |4 aut | |
| 700 | 1 | |a Huster, Dominik |4 aut | |
| 700 | 1 | |a Grünewald, Thomas |0 (orcid)0000-0002-2955-3085 |4 aut | |
| 700 | 1 | |a Schaade, Lars |4 aut | |
| 700 | 1 | |a Wichmann, Ole |4 aut | |
| 700 | 1 | |a Harder, Thomas |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Infection |d Springer Berlin Heidelberg, 1973 |g 51(2023), 4 vom: 13. März, Seite 1093-1102 |w (DE-627)129393010 |w (DE-600)185104-4 |w (DE-576)014777851 |x 0300-8126 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2023 |g number:4 |g day:13 |g month:03 |g pages:1093-1102 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s15010-023-02012-z |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a SSG-OPC-DE-84 | ||
| 912 | |a GBV_ILN_267 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4305 | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2023 |e 4 |b 13 |c 03 |h 1093-1102 | ||